Range Impact (RNGE) 10-KT 31 Mar 22 2021 FY Annual report (with FYE transition) Financial data

Cover

Cover - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Mar. 30, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-KT
Amendment Flag	false
Document Annual Report	false
Document Transition Report	true
Document Period Start Date	Apr. 1, 2021
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53832
Entity Registrant Name	MALACHITE INNOVATIONS, INC.
Entity Central Index Key	0001438943
Entity Tax Identification Number	75-3268988
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	200 Park Avenue
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Cleveland
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44122
City Area Code	216
Local Phone Number	304-6556
Title of 12(b) Security	Common Stock
Trading Symbol	MLCT
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float				$ 7,104,169
Entity Common Stock, Shares Outstanding			51,450,147
Auditor Firm ID	314	572
Auditor Name	MEADEN & MOORE, LTD.	Weinberg & Company, P.A
Auditor Location	Cleveland, Ohio	Los Angeles, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 38,343	$ 884,137
Prepaid expenses	3,884	3,195
Total current assets	42,227	887,332
Deposits	8,692	9,502
Total Assets	50,919	896,834
Current Liabilities
Accounts payable and accrued liabilities	82,560	33,440
Line of credit	350,000
Total liabilities	432,560	33,440
Stockholders’ Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 51,450,147 and 50,840,147 shares issued and outstanding, respectively	51,250	50,640
Additional paid-in-capital	48,707,787	48,240,463
Accumulated deficit	(49,140,678)	(47,427,709)
Total stockholders’ equity (deficit)	(381,641)	863,394
Total Liabilities and Stockholders’ Equity	$ 50,919	$ 896,834

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	51,450,147	50,840,147
Common stock, shares outstanding	51,450,147	50,840,147

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Income Statement [Abstract]
Revenues
Operating Expenses:
General and administrative	1,413,774	1,929,308
Research and development	298,925	408,905
Total operating expenses	1,712,699	2,338,213
Loss from operations	(1,712,699)	(2,338,213)
Other income:
Gain on extinguishment of liabilities		1,456,574
Other income (expense)	(270)	788
Total other income (expense)	(270)	1,457,362
Net loss	$ (1,712,969)	$ (880,851)
Net loss per share – basic and diluted	$ (0.03)	$ (0.02)
Weighted average number of common shares outstanding – basic and diluted	50,968,292	50,840,147

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Mar. 31, 2020	$ 50,640	$ 47,778,607	$ (46,546,858)	$ 1,282,389
Balance, shares at Mar. 31, 2020	50,840,147
Fair value of vested stock options		461,856		461,856
Net Loss			(880,851)	(880,851)
Balance at Mar. 31, 2021	$ 50,640	48,240,463	(47,427,709)	863,394
Balance, shares at Mar. 31, 2021	50,840,147
Fair value of vested stock options		297,984		297,984
Net Loss			(1,712,969)	(1,712,969)
Cancellation of shares	$ (140)	140
Cancellation of shares, shares	(140,000)
Issuance of common stock and warrants	$ 750	169,200		169,950
Issuance of common stock and warrants, shares	750,000
Balance at Dec. 31, 2021	$ 51,250	$ 48,707,787	$ (49,140,678)	$ (381,641)
Balance, shares at Dec. 31, 2021	51,450,147

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (1,712,969)	$ (880,851)
Adjustments to reconcile loss from operations to net cash used in operating activities:
Fair value of vested stock options	297,984	461,856
Operating lease expense		123,606
Gain on extinguishment of liabilities, net of cash received of $450,000		(1,006,574)
Accrual of interest added to note payable		528
Changes in operating assets and liabilities:
Prepaid expense and other current assets	(689)	12,471
Accounts payable and accrued liabilities	49,120	(216,683)
Deposits	810	26,250
Operating lease liability		(125,679)
Net cash used in operating activities	(1,365,744)	(1,605,076)
Cash provided by financing activities:
Proceeds from issuance of common shares and warrants	169,950
Proceeds from line of credit	350,000
Proceeds from PPP loan		96,988
Net cash provided by financing activities	519,950	96,988
Net decrease in cash and cash equivalents	(845,794)	(1,508,088)
Cash and cash equivalents - beginning of period	884,137	2,392,225
Cash and cash equivalents - end of period	38,343	884,137
Supplemental disclosure of cash flow information:
Income taxes	2,400	800
Supplemental non-cash investing and financing activities:
Cancellation of shares	$ (140)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Dec. 31, 2021USD ($)
Statement of Cash Flows [Abstract]
Cash received on settlement	$ 450,000

BUSINESS OPERATIONS AND SUMMARY

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Malachite Innovations, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. Originally founded in 2007 as Legend Mining Inc., the Company began operations as a mineral extraction exploration business. In 2011, the Company changed its name to Stevia First Corp and pursued a new strategy focused on developing stevia-based additives for the food and beverage industry. In 2015, the Company changed its name to Vitality Biopharma, Inc. and pursued a new strategy focused on developing cannabinoid-based prodrugs anticipated to treat inflammatory conditions of the gastrointestinal tract by unlocking the therapeutic properties of cannabinoids but without their unwanted psychoactive side effects. In October 2021, the Company changed its name to Malachite Innovation, Inc. and reorganized its corporate structure and created the following two wholly-owned operating subsidiaries: (i) Graphium Biosciences, Inc., a Nevada corporation (“Graphium”), into which the Company contributed all of its drug development assets; and (ii) Daedalus Ecosciences, Inc., a Nevada corporation (“Daedalus”). Graphium plans to focus its business activities on the health and wellness of people, with a particular focus on advancing our broad portfolio of over 100 glycosylated cannabinoid prodrugs. Daedalus plans to focus its business activities on the health and wellness of the planet through ESG investments, with a particular focus on deploying technological innovations and eco-friendly solutions to remedy difficult environmental situations in economically challenged communities. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the nine months ended December 31, 2021, the Company incurred a net loss of $ 1,712,969 1,365,744 The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate as of December 31, 2021, we had sufficient funds to operate the business for 15 months as $650,000 of our $1,000,000 revolving line of credit secured in December 2021 was then available and $4,830,050 of the $5,000,000 equity financing line secured in August 2021 with an institutional investor was available for additional equity issuances through December 31, 2022. Although our existing cash balances and the availability of funds under our equity financing line are estimated to be sufficient to fund our currently planned level of operations, we are actively seeking additional financing and other sources of capital to fund our planned future operations at a lower cost of capital. However, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. No assurance can be given that any future financing or capital, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. We do not presently have significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term. Since inception, the Company has experienced recurring operating losses and negative operating cash flows, and we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the near term, with longer-term funding expected to come from revenue and profits from the anticipated ESG investments of our Daedalus Ecosciences subsidiary. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Graphium Biosciences, Inc., Daedalus Ecosciences, Inc., and Vitality Healthtech, Inc. (dissolved in May 2021), and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is December 31. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The more significant estimates and assumptions by management include, among others, assumptions used in valuing assets acquired in business acquisitions, reserves for accounts receivable, assumptions used in valuing equity instruments issued for services, the valuation allowance for deferred tax assets, and accruals for potential liabilities. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company had no lease commitments for longer than one year as of December 31, 2021. The laboratory space lease in Rocklin, California was renewed in March 2022 and ends on March 31, 2023. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE December 31, 2021 March 31, 2021 Options 6,882,544 5,997,544 Warrants 646,668 146,668 Total 7,529,212 6,144,212 Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred. Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments” requires that the Company disclose estimated fair values of financial instruments. Financial instruments held by the Company include, among others, accounts payable. The carrying amounts reported in the balance sheets for assets and liabilities qualifying as financial instruments are a reasonable estimate of fair value. Segments As of October 1, 2021, we began operating under two segments: (i) Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company, will report the operating results of our health and wellness innovations serving people, with a particular focus on advancing our broad portfolio of over 100 glycosylated cannabinoid prodrugs, and (ii) Daedalus Ecosciences, Inc., a wholly-owned subsidiary of the Company, will report the operating results of our health and wellness innovations serving the planet, with a particular focus on deploying technological innovations and eco-friendly solutions to remedy difficult environmental situations in economically challenged communities. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

GAIN ON EXTINGUISHMENT OF LIABI

GAIN ON EXTINGUISHMENT OF LIABILITIES	9 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
GAIN ON EXTINGUISHMENT OF LIABILITIES	2. GAIN ON EXTINGUISHMENT OF LIABILITIES SCHEDULE OF GAIN ON EXTINGUISHMENT OF LIABILITIES Nine Months Year Ended Gain on settlement with vendor (a) $ - $ 1,062,405 Gain on extinguishment of advance (b) - 296,653 Gain on forgiveness of PPP Loan (c) - 97,516 Gain on extinguishment of debt $ - $ 1,456,574 (a) Gain on settlement with vendor From 2016 to 2019, the Company recorded approximately $ 1.1 612,405 612,405 450,000 1,062,405 (b) Gain on extinguishment of advance In July 2018, the Company received a payment from a third party in the amount of $ 296,653 296,653 (c) Gain on forgiveness of PPP Loan On May 6, 2020, the Company was granted a loan (the “PPP loan”) from U.S. Bank for $ 96,988 1 528 97,516

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	3. STOCK OPTIONS Stock options issued during the nine months ended December 31, 2021 During the nine months ended December 31, 2021, the Company granted to directors and employees options to purchase an aggregate of 1,150,000 shares of the Company’s common stock with exercise prices of $ 0.277 per share that expire ten years from the date of grant, and vested upon grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes-Merton Option Pricing model based on the following assumptions: (i) volatility rate of 385.62 %, (ii) discount rate of 1.25 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $ 251,455 , all of which was allocated to general and administrative expenses during the nine months ended December 31, 2021. During the nine months ended December 31, 2021, we cancelled options to purchase 265,000 shares of common stock that had been issued to two employees under the prior stock incentive plan. These options were exchanged for options to purchase 242,256 1,150,000 Stock options issued during the year ended March 31, 2021 The Company granted no option awards during the year ended March 31, 2021. During the nine months ended December 31, 2021 and the year ended March 31, 2021, total stock-based compensation expense related to vested stock options was $ 297,984 461,856 A summary of the Company’s stock option activity during the nine months ended December 31, 2021 and the year ended March 31, 2021 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at March 31, 2020 6,546,710 $ 0.89 Granted - - Exercised (32,500 ) 2.17 Expired - - Forfeited (516,666 ) 1.42 Balance outstanding at March 31, 2021 5,997,544 $ 0.91 Granted 1,150,000 0.277 Exchanged (265,000 ) Exercised - - Expired - - Forfeited - - Balance outstanding at December 31, 2021 6,882,544 $ 0.69 Balance exercisable at December 31, 2021 6,882,544 $ 0.69 At December 31, 2021, the 6,882,544 no A summary of the Company’s stock options outstanding and exercisable as of December 31, 2021 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Number of Options Weighted Average Exercise Price Weighted Average Grant- date Stock Price Options Outstanding, December 31, 2021 1,150,000 $ 0.277 $ 0.2770 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 350,834 $ 1.50 1.95 $ 1.50 1.95 607,500 $ 2.00 2.79 $ 2.00 2.79 83,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 6,882,544 Options Exercisable, December 31, 2021 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 350,834 $ 1.50 1.95 $ 1.50 1.95 607,500 $ 2.00 2.79 $ 2.00 2.79 83,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 6,882,544

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	4. STOCKHOLDERS’ EQUITY Issuance of Common Stock and Warrants In September 2021, pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission, the Company sold 500,000 shares of its common stock and warrants to purchase 500,000 shares of the Company’s common stock with a term of five years 119,000 . The common stock and warrants were sold under an equity financing line to a single investor, at a price of $ 0.238 per share and the exercise price for the warrants of $ 0.32 per share. Pursuant to the same registration statement, the Company sold 250,000 shares of its common stock to a single investor for $ 50,950 in October 2021. Pursuant to an agreement between the Company and the investor, no warrants were issued as part of the sale in October 2021.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2021
Warrants
WARRANTS	5. WARRANTS A summary of warrants to purchase common stock issued during the nine months ended December 31, 2021 and the year ended March 31, 2021 is as follows: SUMMARY OF WARRANTS ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at March 31, 2020 1,135,003 $ 2.19 Granted - - Exercised - - Expired (988,335 ) 2.10 Balance outstanding at March 31, 2021 146,668 $ 3.00 Granted 500,000 0.32 Exercised - - Expired - - Balance outstanding and exercisable at December 31, 2021 646,668 $ 1.08 At December 31, 2021, the 646,668 no 146,668 no

LINE OF CREDIT

LINE OF CREDIT	9 Months Ended
	Dec. 31, 2021
Line Of Credit
LINE OF CREDIT	6. LINE OF CREDIT In November 2021, the Company secured a line of credit with a bank with a limit of $ 1,000,000 November 30, 2023 1 350,000

INCOME TAXES

INCOME TAXES	9 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	7. INCOME TAXES The Company had no SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION Nine Months Year Ended Federal statutory tax rate (21 )% (21 )% State tax rate, net of federal benefit (7 )% (7 )% Total federal and state tax rate (28 )% (28 )% Valuation allowance 28 % 28 % Effective tax rate - % - % Deferred tax assets and liabilities consist of the following: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, 2021 March 31, 2021 Net deferred tax assets: Net operating loss carryforwards $ 5,938,000 $ 5,531,000 Stock-based compensation 3,284,000 3,200,000 Research credits 64,000 64,000 Operating lease liability - - Gross deferred tax assets 9,286,000 8,795,000 Less: valuation allowance (8,178,000 ) (7,687,000 ) Total deferred tax assets 1,108,000 1,108,000 Deferred tax liabilities: Derivative income 1,108,000 1,108,000 Operating lease right-of-use asset - - Total deferred tax liabilities 1,108,000 1,108,000 Net deferred income tax assets (liabilities) $ - $ - The provisions of ASC Topic 740, Accounting for Income Taxes 491,000 29,000 At December 31, 2021 and March 31, 2021, the Company had available Federal and state net operating loss carryforwards (“NOLs”) to reduce future taxable income. For Federal purposes, the amounts available were approximately $ 22.3 20.8 17.9 16.8 The Federal carryforwards expire on various dates through 2041 and the state carryforwards expire through 2038. The Company’s operations are based in California and Ohio and it is subject to Federal, California and Ohio state income tax. Tax years after 2016 are open to examination by United States and state tax authorities. The Company adopted the provisions of ASC 740, which requires companies to determine whether it is “more likely than not” that a tax position will be sustained upon examination by the appropriate taxing authorities before any tax benefit can be recorded in the financial statements. ASC 740 also provides guidance on the recognition, measurement, classification and interest and penalties related to uncertain tax positions. As of December 31, 2021 and March 31, 2021, no

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES The Company received a letter in February 2021 from counsel for the Company’s director’s and officer’s insurance carrier (the “insurer”) demanding that the Company reimburse the insurer for sums advanced by the insurer to a former director of the Company as defense costs in connection with a claim purportedly arising under a previous directors and officers insurance policy. The Company believes it has no liability for this claim on the basis of, among other things, Nevada law, the Company’s governing documents and the language of the policy. Accordingly, as of December 31, 2021, no contingent liability has been recorded in the Company’s consolidated statements of financial condition for this matter.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	9. SEGMENT INFORMATION ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services, categories, business segments and major customers in financial statements. The Company has two reportable segments that are based on the following business units: Research & Development and ESG Operations. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. The Company operates two ● Cannabinoid Prodrug Operations – research and development primarily related to the Company’s cannabinoid pharmaceuticals ● Environmental, Social and Governance (ESG) Operations – development of innovations addressing the health and wellness of the planet, with a particular focus on deploying technological innovations and eco-friendly solutions to remedy difficult environmental situations in economically challenged communities The Company had no inter-segment sales for the periods presented. Summarized financial information concerning the Company’s reportable segments is shown as below: By Categories SUMMARY OF REPORTABLE SEGMENT TABLE TEXT BLOCK For the nine months ended December 31, 2021 Cannabinoid Prodrug Operations ESG Operations Corporate Total Net Loss $ (298,925 ) $ (17,484 ) $ (1,396,560 ) $ (1,712,969 ) Total assets 8,134 - 42,785 50,919 Capital expenditures for long-lived assets $ - $ - $ - $ - For the year ended March 31, 2021 Cannabinoid Prodrug Operations ESG Operations Corporate Total Net loss $ (408,905 ) $ - $ (471,946 ) $ (880,851 ) Total assets - - 896,934 896,834 Capital expenditures for long-lived assets $ - $ - $ - $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS In January and February 2022, the Company drew a total of $ 400,000 on the line of credit described in Note 6 to fund ordinary course operations. In March 2022, the Company entered into a non-binding letter of intent (the “Letter of Intent”) with the owners of Range Environmental Resources, Inc. (“Range”), a West Virginia-based environmental services company operating throughout Appalachia, to purchase 80% 10,000,000 1,000,000 250,000

BUSINESS OPERATIONS AND SUMMA_2

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the nine months ended December 31, 2021, the Company incurred a net loss of $ 1,712,969 1,365,744 The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate as of December 31, 2021, we had sufficient funds to operate the business for 15 months as $650,000 of our $1,000,000 revolving line of credit secured in December 2021 was then available and $4,830,050 of the $5,000,000 equity financing line secured in August 2021 with an institutional investor was available for additional equity issuances through December 31, 2022. Although our existing cash balances and the availability of funds under our equity financing line are estimated to be sufficient to fund our currently planned level of operations, we are actively seeking additional financing and other sources of capital to fund our planned future operations at a lower cost of capital. However, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. No assurance can be given that any future financing or capital, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. We do not presently have significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term. Since inception, the Company has experienced recurring operating losses and negative operating cash flows, and we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the near term, with longer-term funding expected to come from revenue and profits from the anticipated ESG investments of our Daedalus Ecosciences subsidiary. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations.
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Graphium Biosciences, Inc., Daedalus Ecosciences, Inc., and Vitality Healthtech, Inc. (dissolved in May 2021), and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is December 31.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The more significant estimates and assumptions by management include, among others, assumptions used in valuing assets acquired in business acquisitions, reserves for accounts receivable, assumptions used in valuing equity instruments issued for services, the valuation allowance for deferred tax assets, and accruals for potential liabilities. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Leases	Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company had no lease commitments for longer than one year as of December 31, 2021. The laboratory space lease in Rocklin, California was renewed in March 2022 and ends on March 31, 2023.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE December 31, 2021 March 31, 2021 Options 6,882,544 5,997,544 Warrants 646,668 146,668 Total 7,529,212 6,144,212
Patents and Patent Application Costs	Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred.
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments” requires that the Company disclose estimated fair values of financial instruments. Financial instruments held by the Company include, among others, accounts payable. The carrying amounts reported in the balance sheets for assets and liabilities qualifying as financial instruments are a reasonable estimate of fair value.
Segments	Segments As of October 1, 2021, we began operating under two segments: (i) Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company, will report the operating results of our health and wellness innovations serving people, with a particular focus on advancing our broad portfolio of over 100 glycosylated cannabinoid prodrugs, and (ii) Daedalus Ecosciences, Inc., a wholly-owned subsidiary of the Company, will report the operating results of our health and wellness innovations serving the planet, with a particular focus on deploying technological innovations and eco-friendly solutions to remedy difficult environmental situations in economically challenged communities. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

BUSINESS OPERATIONS AND SUMMA_3

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE December 31, 2021 March 31, 2021 Options 6,882,544 5,997,544 Warrants 646,668 146,668 Total 7,529,212 6,144,212

GAIN ON EXTINGUISHMENT OF LIA_2

GAIN ON EXTINGUISHMENT OF LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
SCHEDULE OF GAIN ON EXTINGUISHMENT OF LIABILITIES	SCHEDULE OF GAIN ON EXTINGUISHMENT OF LIABILITIES Nine Months Year Ended Gain on settlement with vendor (a) $ - $ 1,062,405 Gain on extinguishment of advance (b) - 296,653 Gain on forgiveness of PPP Loan (c) - 97,516 Gain on extinguishment of debt $ - $ 1,456,574 (a) Gain on settlement with vendor From 2016 to 2019, the Company recorded approximately $ 1.1 612,405 612,405 450,000 1,062,405 (b) Gain on extinguishment of advance In July 2018, the Company received a payment from a third party in the amount of $ 296,653 296,653 (c) Gain on forgiveness of PPP Loan On May 6, 2020, the Company was granted a loan (the “PPP loan”) from U.S. Bank for $ 96,988 1 528 97,516

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
SUMMARY OF STOCK OPTION ACTIVITY	A summary of the Company’s stock option activity during the nine months ended December 31, 2021 and the year ended March 31, 2021 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at March 31, 2020 6,546,710 $ 0.89 Granted - - Exercised (32,500 ) 2.17 Expired - - Forfeited (516,666 ) 1.42 Balance outstanding at March 31, 2021 5,997,544 $ 0.91 Granted 1,150,000 0.277 Exchanged (265,000 ) Exercised - - Expired - - Forfeited - - Balance outstanding at December 31, 2021 6,882,544 $ 0.69 Balance exercisable at December 31, 2021 6,882,544 $ 0.69
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE	A summary of the Company’s stock options outstanding and exercisable as of December 31, 2021 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Number of Options Weighted Average Exercise Price Weighted Average Grant- date Stock Price Options Outstanding, December 31, 2021 1,150,000 $ 0.277 $ 0.2770 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 350,834 $ 1.50 1.95 $ 1.50 1.95 607,500 $ 2.00 2.79 $ 2.00 2.79 83,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 6,882,544 Options Exercisable, December 31, 2021 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 350,834 $ 1.50 1.95 $ 1.50 1.95 607,500 $ 2.00 2.79 $ 2.00 2.79 83,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 6,882,544

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2021
Warrants
SUMMARY OF WARRANTS ACTIVITY	A summary of warrants to purchase common stock issued during the nine months ended December 31, 2021 and the year ended March 31, 2021 is as follows: SUMMARY OF WARRANTS ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at March 31, 2020 1,135,003 $ 2.19 Granted - - Exercised - - Expired (988,335 ) 2.10 Balance outstanding at March 31, 2021 146,668 $ 3.00 Granted 500,000 0.32 Exercised - - Expired - - Balance outstanding and exercisable at December 31, 2021 646,668 $ 1.08

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION Nine Months Year Ended Federal statutory tax rate (21 )% (21 )% State tax rate, net of federal benefit (7 )% (7 )% Total federal and state tax rate (28 )% (28 )% Valuation allowance 28 % 28 % Effective tax rate - % - %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	Deferred tax assets and liabilities consist of the following: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, 2021 March 31, 2021 Net deferred tax assets: Net operating loss carryforwards $ 5,938,000 $ 5,531,000 Stock-based compensation 3,284,000 3,200,000 Research credits 64,000 64,000 Operating lease liability - - Gross deferred tax assets 9,286,000 8,795,000 Less: valuation allowance (8,178,000 ) (7,687,000 ) Total deferred tax assets 1,108,000 1,108,000 Deferred tax liabilities: Derivative income 1,108,000 1,108,000 Operating lease right-of-use asset - - Total deferred tax liabilities 1,108,000 1,108,000 Net deferred income tax assets (liabilities) $ - $ -

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
SUMMARY OF REPORTABLE SEGMENT TABLE TEXT BLOCK	Summarized financial information concerning the Company’s reportable segments is shown as below: By Categories SUMMARY OF REPORTABLE SEGMENT TABLE TEXT BLOCK For the nine months ended December 31, 2021 Cannabinoid Prodrug Operations ESG Operations Corporate Total Net Loss $ (298,925 ) $ (17,484 ) $ (1,396,560 ) $ (1,712,969 ) Total assets 8,134 - 42,785 50,919 Capital expenditures for long-lived assets $ - $ - $ - $ - For the year ended March 31, 2021 Cannabinoid Prodrug Operations ESG Operations Corporate Total Net loss $ (408,905 ) $ - $ (471,946 ) $ (880,851 ) Total assets - - 896,934 896,834 Capital expenditures for long-lived assets $ - $ - $ - $ -

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,529,212	6,144,212
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,882,544	5,997,544
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	646,668	146,668

BUSINESS OPERATIONS AND SUMMA_4

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Mar. 31, 2021
Accounting Policies [Abstract]
Net loss		$ 1,712,969	$ 880,851
Net cash used in operating activities		$ 1,365,744	$ 1,605,076
Substantial Doubt about Going Concern, Conditions or Events	We estimate as of December 31, 2021, we had sufficient funds to operate the business for 15 months as $650,000 of our $1,000,000 revolving line of credit secured in December 2021 was then available and $4,830,050 of the $5,000,000 equity financing line secured in August 2021 with an institutional investor was available for additional equity issuances through December 31, 2022. Although our existing cash balances and the availability of funds under our equity financing line are estimated to be sufficient to fund our currently planned level of operations, we are actively seeking additional financing and other sources of capital to fund our planned future operations at a lower cost of capital. However, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. No assurance can be given that any future financing or capital, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.

SCHEDULE OF GAIN ON EXTINGUISHM

SCHEDULE OF GAIN ON EXTINGUISHMENT OF LIABILITIES (Details) - USD ($)		9 Months Ended	12 Months Ended
		Dec. 31, 2021	Mar. 31, 2021
Debt Disclosure [Abstract]
Gain on settlement with vendor (a)	[1]		$ 1,062,405
Gain on extinguishment of advance (b)	[2]		296,653
Gain on forgiveness of PPP Loan (c)	[3]		97,516
Gain on extinguishment of debt			$ 1,456,574
[1]	Gain on settlement with vendor
[2]	Gain on extinguishment of advance
[3]	Gain on forgiveness of PPP Loan

SCHEDULE OF GAIN ON EXTINGUIS_2

SCHEDULE OF GAIN ON EXTINGUISHMENT OF LIABILITIES (Details) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Nov. 30, 2020	Nov. 21, 2020	May 06, 2020	Dec. 31, 2019
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Due to vendor						$ 1,100,000
Accounts payable to vendor			$ 612,405
Gain on settlement of outstanding invoices		$ 612,405
Payment from vendor		450,000
Gain on settlement		1,062,405
Gain from debt extinguishment		1,456,574
Paycheck Protection Program [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Gain from debt extinguishment		97,516
Payment from third party		296,653
Accrued interest				$ 528
Paycheck Protection Program [Member] | U.S. Bank [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Loans payable					$ 96,988
Debt instrument, interest rate					1.00%
Third party [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Gain from debt extinguishment		$ 296,653

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance Outstanding	5,997,544	6,546,710
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.91	$ 0.89
Shares, Granted	1,150,000
Weighted Average Exercise Price, Outstanding Granted	$ 0.277
Shares, Exercised		(32,500)
Weighted Average Exercise Price, Outstanding Exercised		$ 2.17
Shares, Expired
Weighted Average Exercise Price, Outstanding Expired
Shares, Forfeited		(516,666)
Weighted Average Exercise Price, Outstanding Forfeited		$ 1.42
Shares, Exchanged	(265,000)
Shares Outstanding, Ending Balance	6,882,544	5,997,544
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.69	$ 0.91
Shares, Balance Exercisable	6,882,544
Weighted Average Exercise Price, Outstanding Balance exercisable	$ 0.69

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	6,882,544	5,997,544	6,546,710
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.277
Number of Options, Options Exercisable	6,882,544
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	1,150,000
Weighted Average Exercise Price, Options Outstanding	$ 0.277
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.2770
Number of Options, Options Exercisable	1,150,000
Weighted Average Exercise Price, Options Exercisable	$ 0.277
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.277
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	750,000
Weighted Average Exercise Price, Options Outstanding	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30
Number of Options, Options Exercisable	750,000
Weighted Average Exercise Price, Options Exercisable	$ 0.30
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.30
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	2,000,000
Weighted Average Exercise Price, Options Outstanding	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35
Number of Options, Options Exercisable	2,000,000
Weighted Average Exercise Price, Options Exercisable	$ 0.35
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.35
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	1,664,542
Weighted Average Exercise Price, Options Outstanding	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.50
Number of Options, Options Exercisable	1,664,542
Weighted Average Exercise Price, Options Exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.50
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	128,000
Weighted Average Exercise Price, Options Outstanding	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.96
Number of Options, Options Exercisable	128,000
Weighted Average Exercise Price, Options Exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.96
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	130,000
Weighted Average Exercise Price, Options Outstanding	$ 1
Weighted Average Grant-date Stock Price, Options Outstanding	$ 10
Number of Options, Options Exercisable	130,000
Weighted Average Exercise Price, Options Exercisable	$ 1
Weighted Average Grant-date Stock Price, Options Exercisable	$ 10
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	350,834
Number of Options, Options Exercisable	350,834
Stock Options Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding	1.50
Weighted Average Exercise Price, Options Exercisable	1.50
Weighted Average Grant-date Stock Price, Options Exercisable	1.50
Stock Options Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	1.95
Weighted Average Grant-date Stock Price, Options Outstanding	1.95
Weighted Average Exercise Price, Options Exercisable	1.95
Weighted Average Grant-date Stock Price, Options Exercisable	$ 1.95
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	607,500
Number of Options, Options Exercisable	607,500
Stock Options Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 2
Weighted Average Grant-date Stock Price, Options Outstanding	2
Weighted Average Exercise Price, Options Exercisable	2
Weighted Average Grant-date Stock Price, Options Exercisable	2
Stock Options Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2.79
Weighted Average Grant-date Stock Price, Options Outstanding	2.79
Weighted Average Exercise Price, Options Exercisable	2.79
Weighted Average Grant-date Stock Price, Options Exercisable	$ 2.79
Stock Options Nine[Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	83,334
Number of Options, Options Exercisable	83,334
Stock Options Nine[Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding	3.10
Weighted Average Exercise Price, Options Exercisable	3.10
Weighted Average Grant-date Stock Price, Options Exercisable	3.10
Stock Options Nine[Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.80
Weighted Average Grant-date Stock Price, Options Outstanding	3.80
Weighted Average Exercise Price, Options Exercisable	3.80
Weighted Average Grant-date Stock Price, Options Exercisable	$ 3.80
Stock Options Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	18,334
Number of Options, Options Exercisable	18,334
Stock Options Ten [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 4
Weighted Average Grant-date Stock Price, Options Outstanding	4
Weighted Average Exercise Price, Options Exercisable	4
Weighted Average Grant-date Stock Price, Options Exercisable	4
Stock Options Ten [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4.70
Weighted Average Grant-date Stock Price, Options Outstanding	4.70
Weighted Average Exercise Price, Options Exercisable	4.70
Weighted Average Grant-date Stock Price, Options Exercisable	$ 4.70

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,150,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.277
Stock based compensation vested stock option	$ 297,984	$ 461,856
Outstanding stock options	6,882,544	5,997,544	6,546,710
Stock warrants, intrinsic value	$ 0
Directors And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,150,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.277
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	385.62%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions	1.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Directors And Employees [Member] | New Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	242,256
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	$ 251,455
Two Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Benefit Plan	265,000

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2021	Sep. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		500,000
Warrant term		5 years
Proceeds from Issuance of Common Stock		$ 119,000
Shares Issued, Price Per Share		$ 0.238
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.32
Investor [Member]
Defined Benefit Plan Disclosure [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	250,000
Sale of Stock, Consideration Received on Transaction	$ 50,950

SUMMARY OF WARRANTS ACTIVITY (D

SUMMARY OF WARRANTS ACTIVITY (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Number of Shares, Warrants Outstanding, Beginning Balance	146,668	1,135,003
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 3	$ 2.19
Number of Shares, Warrants Granted	500,000
Weighted Average Exercise Price, Warrants Outstanding, Granted	$ 0.32
Number of Shares, Warrants Exercised
Weighted Average Exercise Price, Warrants Outstanding, Exercised
Number of Shares, Warrants Expired		(988,335)
Weighted Average Exercise Price, Warrants Outstanding, Expired		$ 2.10
Number of Shares, Warrants Expired		988,335
Number of Shares, Warrants Outstanding and Exercisable Ending	646,668	146,668
Weighted Average Exercise Price, Outstanding Balance exercisable	$ 1.08

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Intrinsic value	$ 0
Warrant [Member]
Outstanding warrants	646,668	146,668
Intrinsic value	$ 0	$ 0

LINE OF CREDIT (Details Narrati

LINE OF CREDIT (Details Narrative) - USD ($)	1 Months Ended
	Nov. 30, 2021	Dec. 31, 2021
Line Of Credit
Maximum borrowing capacity, line of credit	$ 1,000,000
Line of credit maturity date	Nov. 30, 2023
Line of credit interest rate	1.00%
Line of credit		$ 350,000

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory tax rate	(21.00%)	(21.00%)
State tax rate, net of federal benefit	(7.00%)	(700.00%)
Total federal and state tax rate	(28.00%)	(28.00%)
Valuation allowance	28.00%	28.00%
Effective tax rate

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,938,000	$ 5,531,000
Stock-based compensation	3,284,000	3,200,000
Research credits	64,000	64,000
Operating lease liability
Gross deferred tax assets	9,286,000	8,795,000
Less: valuation allowance	(8,178,000)	(7,687,000)
Total deferred tax assets	1,108,000	1,108,000
Derivative income	1,108,000	1,108,000
Operating lease right-of-use asset
Total deferred tax liabilities	1,108,000	1,108,000
Net deferred income tax assets (liabilities)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Increased in valuation allowances	491,000	29,000
Federal net operating loss carryforwards	22,300,000	20,800,000
State net operating loss carryforwards	$ 17,900,000	16,800,000
Income tax description	The Federal carryforwards expire on various dates through 2041 and the state carryforwards expire through 2038.
Liability for unrecognized tax benefits	$ 0	$ 0

SUMMARY OF REPORTABLE SEGMENT T

SUMMARY OF REPORTABLE SEGMENT TABLE TEXT BLOCK (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Segment Reporting Information [Line Items]
Net Loss	$ (1,712,969)	$ (880,851)
Total assets	50,919	896,834
Capital expenditures for long-lived assets
Cannabinoid Prodrug Operations [Member]
Segment Reporting Information [Line Items]
Net Loss	(298,925)	(408,905)
Total assets	8,134
Capital expenditures for long-lived assets
ESG Operations [Member]
Segment Reporting Information [Line Items]
Net Loss	(17,484)
Total assets
Capital expenditures for long-lived assets
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Net Loss	(1,396,560)	(471,946)
Total assets	42,785	896,934
Capital expenditures for long-lived assets

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Dec. 31, 2021Segments
Segment Reporting [Abstract]
Number of reportable segments	2

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Feb. 28, 2022	Jan. 31, 2022
Subsequent Event [Line Items]
Number of shares issued		500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity			$ 400,000	$ 400,000
Subsequent Event [Member] | Range Environmental Resources Inc [Member]
Subsequent Event [Line Items]
Percentage of shares purchased	80.00%
Number of shares issued	10,000,000
Sale of stock consideration	$ 1,000,000
Restricted cash	$ 250,000